Eli Lilly and Company $LLY Shares Bought by Curio Wealth LLC

Key Points

• Curio Wealth LLC dramatically increased its stake in Eli Lilly and Company by 14,166.7% in Q2, now holding 428 shares worth $334,000.
• CEO David A. Ricks purchased 1,632 shares at around $644.77 each, increasing his ownership by 0.30%, representing a total value of approximately $352 million.
• Analyst ratings for Eli Lilly are largely positive, with an average target price of $938.61 and several firms assigning a "buy" or "outperform" rating.

Curio Wealth LLC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 14,166.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 428 shares of the company's stock after acquiring an additional 425 shares during the quarter. Curio Wealth LLC's holdings in Eli Lilly and Company were worth $334,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd increased its stake in Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after purchasing an additional 85 shares during the last quarter. GAMMA Investing LLC increased its stake in Eli Lilly and Company by 25.8% in the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock valued at $14,866,000 after purchasing an additional 3,696 shares during the last quarter. Finally, Alpine Bank Wealth Management acquired a new position in Eli Lilly and Company in the first quarter valued at $903,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on LLY. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. BMO Capital Markets boosted their price target on Eli Lilly and Company from $840.00 to $930.00 and gave the company an "outperform" rating in a research report on Monday, October 20th. HSBC boosted their price target on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Leerink Partners reissued a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, JPMorgan Chase & Co. lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $938.61.

Insider Buying and Selling

In related news, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $825.86 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The business has a 50-day moving average of $768.01 and a 200-day moving average of $768.14. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $781.65 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 earnings per share. The company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.